ArticleBMC psychiatry2019
Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental.
Article in BMC psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Pooled it
- Individualizing rTMS in treatment-resistant depression from patient-specific perfusion abnormalities a proof-of-concept randomized trial in comparison to standard rTMS and tDCS.European archives of psychiatry and clinical neuroscience · 2025Trial
- Real-World Effectiveness and Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: A Retrospective Observational Study.Healthcare (Basel, Switzerland) · 2026Article
- Social position and antidepressant dose trajectories: a latent class analysis of a french cohort linked to the reimbursement register.Social psychiatry and psychiatric epidemiology · 2026Article
- Article
- Physical Therapy for Treatment-Resistant Depression A Comprehensive Review of Efficacy, Safety, and Evidence Grading.Neuropsychiatric disease and treatment · 2026Review
- Complications and Ethical Challenges in Neurosurgery for Psychiatric Disorders.Brain sciences · 2025Review
- Higher neutrophil-lymphocyte ratio predicts poor response to repetetive transcranial magnetic stimulation(rTMS) in treatment resistant depression.European archives of psychiatry and clinical neuroscience · 2025Article
- Lithium Augmentation in Treatment-Resistant Depression: A Qualitative Review of the Literature.Pharmacotherapy · 2025Review
- Use of psychostimulants in the management of treatment-resistant major depressive disorder.The mental health clinician · 2025Article
- Expert Guidelines on the Use of Cariprazine in Bipolar I Disorder: Consensus from Southeast Asia.Healthcare (Basel, Switzerland) · 2025Article
- The use of thyroid hormones in the treatment of euthyroid patients with treatment-resistant depression. Data from a survey of 5695 European national endocrine professional organization members.Frontiers in endocrinology · 2025Article
- Is there a risk of esketamine misuse in clinical practice?Therapeutic advances in drug safety · 2025Review
- Evaluating the risk of mild serotonin syndrome in primary care: a retrospective case series of patients with treatment-resistant depression.AME case reports · 2025Article
- Multiomics and blood-based biomarkers of electroconvulsive therapy in severe and treatment-resistant depression: study protocol of the DetECT study.European archives of psychiatry and clinical neuroscience · 2024Article
- Treatment-Resistant Depression in Older Adults.The New England journal of medicine · 2024Review
- Major challenges in youth psychopathology: treatment-resistant depression. A narrative review.Frontiers in psychiatry · 2024Review
- Use of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression in Routine Practice: A Real-World French Study.Depression and anxiety · 2024Article
- Improved clinical outcome prediction in depression using neurodynamics in an emotional face-matching functional MRI task.Frontiers in psychiatry · 2024Article
- Patient experiences of treatment-resistant depression (TRD): A systematic review and qualitative meta-synthesis.PLOS mental health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 13 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClear guidance for successive antidepressant pharmacological treatments for non-responders in major depression is not well established.
methodBased on the RAND/UCLA Appropriateness Method, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental developed expert consensus guidelines for the management of treatment-resistant depression. The expert guidelines combine scientific evidence and expert clinicians' opinions to produce recommendations for treatment-resistant depression. A written survey comprising 118 questions related to highly-detailed clinical presentations was completed on a risk-benefit scale ranging from 0 to 9 by 36 psychiatrist experts in the field of major depression and its treatments. Key-recommendations are provided by the scientific committee after data analysis and interpretation of the results of the survey.
resultsThe scope of these guidelines encompasses the assessment of pharmacological resistance and situations at risk of resistance, as well as the pharmacological and psychological strategies in major depression.
conclusionThe expert consensus guidelines will contribute to facilitate treatment decisions for clinicians involved in the daily assessment and management of treatment-resistant depression across a number of common and complex clinical situations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.